Deals: Are They Really Good for Academia?
Deals: Are They Really Good for Academia? By Leonard Zwelling Once again, a deal has been announced between MD Anderson and a commercial entity. This one is with Immatics. http://www.fiercebiotech.com/story/immatics-md-anderson-partner-60m-immuno-oncology-t-cell-spinout/2015-08-25?utm_medium=nl&utm_source=internal If I understand it correctly, the deal sounds great. There appears to be almost $60M coming to Anderson in private cash and grants […]
Deals: Are They Really Good for Academia? Read More »